In an interview at the 2023 SCOPE conference with ACT editor, Andy Studna, Sunny Kumar, MD, partner at GSR Ventures talks about his recently-founded company and its mission to reduce readmissions for high-risk patients with chronic diseases using voice-enabled natural language processing technology.
Three Must-Dos for Tracking Research and Development of Monoclonal Antibodies
November 2nd 2023There is an expanding array of potential antibody-based treatment options, such as bispecific or multispecific antibodies, that show promise in addressing conditions such as cancer, engineered antibody fragments, or even antibody-drug conjugates.